Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2)
antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). …

Enhancing the efficacy of proteasome inhibitors (PI) is a central goal in myeloma therapy. We
proposed that signaling-level responses after PI may reveal new mechanisms of action that …

The clinical outcome of SARS-CoV-2 infection varies widely between individuals. Machine
learning models can support decision making in healthcare by assessing fatality risk in …

Plasma cells, the malignant cells in multiple myeloma (MM), express high levels of CD38.
Daratumumab, the first CD38-targeting therapeutic antibody, is well tolerated and is effective …

The myeloma bone marrow microenvironment promotes proliferation of malignant plasma
cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central …

While much work has been done in associating differentially methylated positions (DMPs) to
type 2 diabetes (T2D) across different populations, not much attention has been placed on …

A major driver of multiple myeloma (MM) is thought to be aberrant signaling, yet no kinase
inhibitors have proven successful in the clinic. Here, we employed an integrated, systems …

Background. Human cytomegalovirus (HCMV) is a herpesvirus with both lytic and latent life
cycles. Human cytomegalovirus encodes 2 viral cytokines that are orthologs of human …

Proteasome inhibitor (PI) resistance remains a central challenge in multiple myeloma. To
identify pathways mediating resistance, we first mapped proteasome-associated genetic co-…

BackgroundChromosome 22q11.2 deletion syndrome (22q11DS) is associated with high
rates of psychiatric disorders, including schizophrenia in up to 30% of individuals with the …